Fucoidan
A sulphated polysaccharide from brown seaweed. Several small randomized trials show it shifts immune markers, but none has shown that it reduces infections or illness.
Evidence last reviewed: August 2026
What the science says
- Better antibody response to influenza vaccine in older adults Limited evidence
A randomized trial in elderly Japanese men and women found that fucoidan supplementation increased antibody titres after seasonal influenza vaccination. The trial was small and measured antibody levels, not whether anyone actually got influenza.
- Immune and inflammatory markers shift in patients Limited evidence
A randomized, double-blind, placebo-controlled trial of oligo-fucoidan in asthma reported changes in immune and inflammatory measures and in some pulmonary function parameters. Marker-level results in one small trial do not establish a clinical benefit.
- No trials of infection rates Limited evidence
Across the fucoidan literature the outcomes are laboratory measures — cytokines, natural killer cell activity, antibody titres. No trial has used incidence or duration of infection as its endpoint.
Dosage & safety
Scientific references
- Supplementation of elderly Japanese men and women with fucoidan from seaweed increases immune responses to seasonal influenza vaccination
- Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial
Where to buy
Referral link — this site may earn a commission on purchases.
Related in Immunity
- Vitamin C Limited evidence
- Zinc Moderate evidence
- Elderberry Limited evidence
- L-Lysine Limited evidence
- Echinacea Limited evidence
- Andrographis Moderate evidence